The role of stem cell transplantation in chronic lymphocytic leukemia

Seminars in Hematology

Volumn 41, Issue 3, 2004, Pages 246-253

  Rizouli, V ^a   Gribben, J G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MONOCLONAL ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INFECTION; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; REMISSION; REVIEW; STEM CELL TRANSPLANTATION;

EID: 3242668097     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.05.006     Document Type: Article

References (65)

1. Rozman C., Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 333:1995;1052-1057
2. Catovsky D., Murphy R.L. Key issues in the treatment of chronic lymphocytic leukemia. Eur J Cancer. 31A:1995;2146-2154
3. Mauro F.R., Foa R., Giannarelli D., Cordone I., Crescenzi S., Pescarmona E., et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients A single institution study of 204 cases. Blood. 94:1999;448-454
4. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood. 46:1975;219-234
5. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48:1981;198-206
6. Montserrat E., Gomis F., Vallespi T., Rios A., Romero A., Soler J., et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood. 78:1991;1545-1551
7. Juliusson G., Oscier D.G., Fitchett M., Ross F.M., Stockdill G., Mackie M.J., et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 323:1990;720-724
8. Oscier D.G. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia. Blood Rev. 8:1994;88-97
9. Matutes E., Oscier D., Garcia-Marco J., Ellis J., Copplestone A., Gillingham R., et al. Trisomy 12 defines a group of CLL with atypical morphology Correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 92:1996;383-388
10. Lee J.S., Dixon D.O., Kantarjian H.M., Keating M.J., Talpaz M. Prognosis of chronic lymphocytic leukemia A multivariate regression analysis of 325 untreated patients. Blood. 69:1987;929-936
11. Dhodapkar M., Tefferi A., Su J., Phyliky R.L. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL) A single institution study. Leukemia. 7:1993;1232-1235
12. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 343:2000;1910-1916
13. Fais F., Ghiotto F., Hashimoto S., Sellars B., Valetto A., Allen S.L., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 102:1998;1515-1525
14. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1999;1848-1854
15. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1999;1840-1847
16. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 100:2002;4609-4614
17. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 348:2003;1764-1775
18. Durig J., Nuckel H., Cremer M., Fuhrer A., Halfmeyer K., Fandrey J., et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 17:2003;2426-2434
19. Orchard J.A., Ibbotson R.E., Davis Z., Wiestner A., Rosenwald A., Thomas P.W., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 363:2004;105-111
20. Wiestner A., Rosenwald A., Barry T.S., Wright G., Davis R.E., Henrickson S.E., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 101:2003;4944-4951
21. Sorensen J.M., Vena D.A., Fallavollita A., Chun H.G., Cheson B.D. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute Five-year follow-up report. J Clin Oncol. 15:1997;458-465
22. Keating M.J., Smith T.L., Lerner S., O'Brien S., Robertson L.E., Kantarjian H., et al. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 37:2000;71-85
23. Rabinowe S.N., Soiffer R.J., Gribben J.G., Daley H., Freedman A.S., Daley J., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 82:1993;1366-1376
24. Khouri I.F., Keating M.J., Vriesendorp H.M., Reading C.L., Przepiorka D., Huh Y.O., et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia preliminary results. J Clin Oncol. 12:1994;748-758
25. Michallet M., Archimbaud E., Bandini G., Rowlings P.A., Deeg H.J., Gahrton E., et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med. 124:1996;311-315
26. Michallet M., Thiebaut A., Dreger P., Remes K., Milpied N., Santini G., et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL) A report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol. 108:2000;595-601
27. Jonsson O.G., Kitchens R.L., Scott F.C., Smith R.G. Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. Blood. 76:1990;2072-2079
28. Billadeau D., Blackstadt M., Greipp P., Kyle R.A., Oken M.M., Kay N., et al. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction A technique for sequential quantitation of residual disease. Blood. 78:1991;3021-3029
29. Provan D., Bartlettpandite L., Zwicky C., Neuberg D., Maddocks A., Corradini P., et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 88:1996;2228-2235
30. Esteve J., Villamor N., Colomer D., Cervantes F., Campo E., Carreras E., et al. Stem cell transplantation for chronic lymphocytic leukemia Different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 15:2001;445-451
31. Schetelig J., Thiede C., Bornhauser M., Schwerdtfeger R., Kiehl M., Beyer J., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation The Cooperative German Transplant Study Group. J Clin Oncol. 21:2003;2747-2753
32. Pongers-Willemse M.J., Verhagen O.J., Tibbe G.J., Wijkhuijs A.J., de Haas V., Roovers E., et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 12:1998;2006-2014
33. Donovan J.W., Ladetto M., Zou G., Neuberg D., Poor C., Bowers D., et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 95:2000;2651-2658
34. Ladetto M., Donovan J.W., Harig S., Trojan A., Poor C., Schlossnan R., et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant. 6:2000;241-253
35. Bastion Y., Brice P., Haioun C., Sonet A., Salles G., Marolleau J.P., et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood. 86:1995;3257-3262
36. Haas R., Moos M., Mohle R., Dohner H., Witt B., Goldschmidt H., et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplantation. 17:1996;149-155
37. Sala R., Mauro F.R., Bellucci R., De Propris M.S., Cordone I., Lisci A., et al. Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy. Eur J Haematol. 61:1998;14-20
38. Tournilhac O., Cazin B., Lepretre S., Divine M., Maloum K., Delmer A., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 103:2004;363-365
39. Hassan H.T., Hinz T., Kroger N., Zeller W., Zander A.R. Factors influencing platelet recovery after autologous transplantation of G-CSF-mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients. Clin Lab Haematol. 21:1999;21-27
40. Sutton L., Maloum K., Gonzalez H., Zouabi H., Azar N., Boccaccio C., et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia. 12:1998;1699-1707
41. Montillo M., Tedeschi A., Rossi V., Cairoli R., Pungolino E., Intropido L., et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia. 18:2004;57-62
42. Philip T., Armitage J.O., Spitzer G., Chauvin F., Jagannath S., Cahn J.-P., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 316:1987;1493-1498
43. Itala M., Pelliniemi T.T., Rajamaki A., Remes K. Autologous blood cell transplantation in B-CLL Response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant. 19:1997;647-651
44. Pavletic Z.S., Bierman P.J., Vose J.M., Bishop M.R., Wu C.D., Pierson J.L., et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 9:1998;1023-1026
45. Dreger P., von Neuhoff N., Kuse R., Sonnen R., Glass B., Uharek L., et al. Early stem cell transplantation for chronic lymphocytic leukaemia A chance for cure? Br J Cancer. 77:1998;2291-2297
46. Esteve J., Villamor N., Colomer D., Bosch F., Lopez-Guillermo A., Rovira M., et al. Hematopoietic stem cell transplantation in chronic lymphocytic leukemia A report of 12 patients from a single institution. Ann Oncol. 9:1998;167-172
47. Schey S., Ahsan G., Jones R. Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia A phase II single centre study. Bone Marrow Transplant. 24:1999;989-993
48. Griffiths H., Lea J., Bunch C., Lee M., Chapel H. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 89:1992;374-377
49. Robertson L.E., Huh Y.O., Butler J.J., Pugh W.C., Hirsch-Ginsberg C., Stass S., et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone Clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 80:1993;29-36
50. Zomas A., Mehta J., Powles R., Treleaven J., Iveson T., Singhal S., et al. Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplantation. 14:1994;799-803
51. Mehta J., Powles R., Singhal S., Riley U., Treleaven J., Catovsky D. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. Leuk Lymphoma. 26:1997;83-88
52. Khouri I.F., Przepiorka D., van Besien K., O'Brien S., Palmer J.L., Lerner S., et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 97:1997;466-473
53. Doney K.C., Chauncey T., Appelbaum F.R. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant. 29:2002;817-823
54. Khouri I.F., Keating M.J., Saliba R.M., Champlin R.E. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy. 4:2002;217-221
55. Rondon G., Giralt S., Huh Y., Khouri I., Andersson B., Andreeff M., et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 18:1996;669-672
56. deMagalhaes-Silverman M., Donnenberg A., Hammert L., Lister J., Myers D., Simpson J., et al. Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia. Bone Marrow Transplantation. 20:1997;175-177
57. Khouri I.F., Keating M., Korbling M., Przepiorka D., Anderlini P., O'Brien S., et al. Transplant-lite Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 16:1998;2817-2824
58. Khouri I.F., Saliba R.M., Giralt S.A., Lee M.S., Okoroji G.J., Hagemeister F.B., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 98:2001;3595-3599
59. Khouri I.F., Lee M.S., Saliba R.M., Andersson B., Anderlini P., Couriel D., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia Impact of rituximab on immunomodulation and survival. Exp Hematol. 32:2004;28-35
60. Collins R.H., Pineiro L.A., Agura E.D., Fay J.W. Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transplant. 21:1998;627-628
61. Dearden C.E., Matutes E., Cazin B., Tjonnfjord G.E., Parreira A., Nomdedeu B., et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 98:2001;1721-1726
62. Keating M.J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Koller C., et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 81:1993;2878-2884
63. Gjedde S.B., Hansen M.M. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. Leuk Lymphoma. 21:1996;317-320
64. Johnson S., Smith A.G., Loffler H., Osby E., Juliusson G., Emmerich B., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 347:1996;1432-1438
65. O'Brien S., del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 85:1995;307-318